Edwards Lifesciences Form 144: 26,000 Shares Listed
Edwards Lifesciences reported a Form 144 covering the proposed sale of 26,000 shares of Common Stock on 03/11/2026.
Rhea-AI Filing Summary
Edwards Lifesciences reported a Form 144 covering the proposed sale of 26,000 shares of Common Stock on 03/11/2026. The filing lists Employee Stock Option Exercise - Broker Payment for Cashless Exercise as the transaction method and identifies Charles Schwab & Co. as the broker.
Positive
- None.
Negative
- None.
Insights
Routine exercise-and-cashless disposition recorded by broker.
The Form 144 shows an employee stock option exercise where the broker handled a cashless payment and listed 26,000 shares to be sold on 03/11/2026. This pattern commonly reflects option vesting liquidity rather than open-market timing.
Timing and proceeds details are not in the excerpt; subsequent filings or trade reports would state execution outcomes and cash flows.
Form 144 documents a proposed resale under SEC resale notice requirements.
The filing lists the broker (Charles Schwab & Co.) and the transaction method verbatim: Broker Payment for Cashless Exercise. The entry on 03/11/2026 is a notice of intent to sell and not a confirmation of completed trades.
Cash‑flow recipients and net proceeds are not disclosed in the excerpt; enforcement- or reporting-related conditions are not shown.
FAQ
What does Edwards Lifesciences' (EW) Form 144 report?
What does 'Broker Payment for Cashless Exercise' mean on the Form 144?
Who is the broker listed on the EW Form 144 and why does it matter?
AI-generated analysis. How Rhea-AI works. Not financial advice.